Your browser doesn't support javascript.
loading
Identifying Crohn's disease signal from variome analysis.
Wang, Yanran; Miller, Maximilian; Astrakhan, Yuri; Petersen, Britt-Sabina; Schreiber, Stefan; Franke, Andre; Bromberg, Yana.
Afiliação
  • Wang Y; Department of Biochemistry and Microbiology, Rutgers University, New Brunswick, NJ, USA. ywang@bromberglab.org.
  • Miller M; Department of Biochemistry and Microbiology, Rutgers University, New Brunswick, NJ, USA.
  • Astrakhan Y; Present address: Elastic NV, Jersey City, NJ, USA.
  • Petersen BS; Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, Germany.
  • Schreiber S; Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, Germany.
  • Franke A; Department of Internal Medicine I, University Hospital Schleswig-Holstein, Kiel, Germany.
  • Bromberg Y; Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, Germany.
Genome Med ; 11(1): 59, 2019 09 30.
Article em En | MEDLINE | ID: mdl-31564248
ABSTRACT

BACKGROUND:

After years of concentrated research efforts, the exact cause of Crohn's disease (CD) remains unknown. Its accurate diagnosis, however, helps in management and preventing the onset of disease. Genome-wide association studies have identified 241 CD loci, but these carry small log odds ratios and are thus diagnostically uninformative.

METHODS:

Here, we describe a machine learning method-AVA,Dx (Analysis of Variation for Association with Disease)-that uses exonic variants from whole exome or genome sequencing data to extract CD signal and predict CD status. Using the person-specific coding variation in genes from a panel of only 111 individuals, we built disease-prediction models informative of previously undiscovered disease genes. By additionally accounting for batch effects, we were able to accurately predict CD status for thousands of previously unseen individuals from other panels.

RESULTS:

AVA,Dx highlighted known CD genes including NOD2 and new potential CD genes. AVA,Dx identified 16% (at strict cutoff) of CD patients at 99% precision and 58% of the patients (at default cutoff) with 82% precision in over 3000 individuals from separately sequenced panels.

CONCLUSIONS:

Larger training panels and additional features, including other types of genetic variants and environmental factors, e.g., human-associated microbiota, may improve model performance. However, the results presented here already position AVA,Dx as both an effective method for revealing pathogenesis pathways and as a CD risk analysis tool, which can improve clinical diagnostic time and accuracy. Links to the AVA,Dx Docker image and the BitBucket source code are at https//bromberglab.org/project/avadx/ .
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Crohn / Marcadores Genéticos / Predisposição Genética para Doença / Polimorfismo de Nucleotídeo Único / Metagenoma / Exoma Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Crohn / Marcadores Genéticos / Predisposição Genética para Doença / Polimorfismo de Nucleotídeo Único / Metagenoma / Exoma Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article